About PlasmaGen BioSciences
PlasmaGen BioSciences is a Healthcare company based in Bengaluru (India) founded in 2010 by Vinod Nahar. Plasma-derived biopharmaceuticals including albumin and immunoglobulins are developed. PlasmaGen BioSciences has raised $84.55 million across 5 funding rounds from investors including Eight Roads Ventures, RSM Pharma and Trigenesis Lifesciences. The company has 262 employees. PlasmaGen BioSciences was last valued at $48.28 million in March 2023. Its Indian entity Plasmagen Biosciences Private Limited reported revenue of ₹162 Cr. Its focus areas include Diversified Pharmaceuticals and Drugs.
Company details
PlasmaGen BioSciences was established in 2010 in Bengaluru, India, within the biopharmaceutical sector. Focus is placed on products derived from blood plasma, such as albumin, immunoglobulins, coagulation factors, and specialty therapies. Operations aim to enhance accessibility of these treatments across India and emerging markets, supporting care in plasma protein and specialty therapy areas.
- Headquarters Bengaluru, India
- Employees 262
- Founders Vinod Nahar
- Stage Minicorn
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website plasmagen.com
- Social LinkedIn X Facebook YouTube
- Legal Name Plasmagen Biosciences Private Limited
- Date of Incorporation 07 Sep, 2010
- Jurisdiction Bangalore, Karnataka, India
- Annual Revenue₹162 Cr
FY 2025 · +1558% YoY
- Net Loss-₹97.09 Cr
FY 2025 · -60% margin
- EBITDA-₹44.47 Cr
FY 2025 · -27% margin
- Total Equity Funding$84.55M (USD)
in 5 rounds
- Latest Funding Round$16.73M (USD), Series D
Dec 2025
- InvestorsEight Roads Ventures
& 15 more
- Employee Count262
Associated legal entities of PlasmaGen BioSciences
PlasmaGen BioSciences operates through Plasmagen Biosciences Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Plasmagen Biosciences Private Limited CIN U51909KA2010PTC055077 | Active | 07 Sep 2010 | Bangalore, Karnataka | ₹162 Cr | 262 | 6 | View details |
Apps and channels of PlasmaGen BioSciences
its YouTube channel PlasmaGen BioSciences has 188 subscribers and 30 videos.
Videos from PlasmaGen BioSciences
The most watched videos on PlasmaGen BioSciences's YouTube channel, PlasmaGen BioSciences (188 subscribers). Click a video to play it here.
More on PlasmaGen BioSciences.
Funding Insights of PlasmaGen BioSciences
PlasmaGen BioSciences has successfully raised a total of $84.55M across 5 strategic funding rounds. The most recent funding activity was a Series D round of $16.73 million completed in December 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $84.55M
- Total Rounds 5
- Last Round Series D — $16.73M
- First Round $25M
(Jul 2017)
- Investors Count 16
All 5 funding rounds of PlasmaGen BioSciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2025 | $16.73M | Series D | – | Vins Bio Products | – |
| Sep 2024 | $8.91M | Series C | – | – | |
| Mar 2023 | $27.01M | Series C | $48.28M | Eight Roads Ventures | |
| Sep 2022 | $6.9M | Series B | $41.99M | Eight Roads Ventures | |
| Jul 2017 | $25M | Series B | $••••• | Eight Roads Ventures, F-Prime Capital |
| Date | Valuation | Stage |
|---|---|---|
| Mar 2023 | $48.28M | •••••••• |
| Sep 2022 | $41.99M | •••••••• |
| Jul 2017 | $••••• | •••••••• |
Full valuation and stage history of PlasmaGen BioSciences
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $48.28M (Mar 2023). 16 investors in total: 11 institutional and 5 angel.
Investors in PlasmaGen BioSciences
PlasmaGen BioSciences has secured backing from 16 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Eight Roads Ventures, RSM Pharma and Trigenesis Lifesciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investment and global platform support for startups. | 2008 | eightroads.com | London, United Kingdom | |
Investments in life sciences, technology, healthtech, and crypto sectors from global locations. | fprimecapital.com | |||
Artian is an investment management firm providing portfolio and asset management services to clients. | 2021 | artian.com | London, United Kingdom | |
Provider of infrastructure development services | pathltd.com | Indore, India | ||
Provides comprehensive CDMO services for the pharmaceutical industry. | 1980 | kemwellpharma.com | Bengaluru, India | |
Generics and biosimilar drugs are manufactured in Bengaluru, India. | 2000 | rsmpharma.in | Bengaluru, India | |
| unnatipolymers.tcc.mode | ||||
Arteqin is focused on long-term investment management strategies. | arteqin.com | |||
AK Ashish Kacholia | unknown_111f31901a254c5f9 | |||
AB Anurag Bagaria | Angel investor and entrepreneur, co-founder of KemTree Ventures, focused on early-stage startups | unknown_177765e9ee784afa8 |
Investor details for PlasmaGen BioSciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Plasmagen Biosciences Private Limited (PlasmaGen BioSciences)
Plasmagen Biosciences Private Limited is the primary company behind PlasmaGen BioSciences. The board of Plasmagen Biosciences Private Limited currently have 5 directors; the longest-serving is Vinod Nahar, appointed in 2010. 13 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Vinod Nahar DIN 01562249 | Managing Director | 07 Sep 2010 | 16 yrs 1 mo | Plasmagen Biosciences Private Limited |
| Gopal Sarda DIN 01589702 | Director | 07 Jul 2017 | 9 yrs 3 mo | Plasmagen Biosciences Private Limited |
| Rahul Jain DIN 01589726 | Director | 07 Jul 2017 | 9 yrs 3 mo | Plasmagen Biosciences Private Limited |
| Robert Mark Weisskoff DIN 05122018 | Director | 28 Jul 2017 | 9 yrs 2 mo | Plasmagen Biosciences Private Limited |
| Prem Venkatachalam Pavoor DIN 05268309 | Director | 28 Jul 2017 | 9 yrs 2 mo | Plasmagen Biosciences Private Limited |
People of PlasmaGen BioSciences
1 people are tracked at PlasmaGen BioSciences (1 in leadership); the tracked headcount is 262.
| Name | Role | Group |
|---|---|---|
| Founder & Managing Director | Leadership |
Complete people profiles for PlasmaGen BioSciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of PlasmaGen BioSciences
Figures of Plasmagen Biosciences Private Limited, the primary company behind PlasmaGen BioSciences, for FY 2025. Revenue was ₹162 Cr (+1558% year on year). Net loss was -₹97.09 Cr (-60% margin). EBITDA was -₹44.47 Cr (-27% margin). Revenue has grown at a compounded annual rate of +16% over three years and +7% over five years.
- ₹162 CrRevenue · FY 2025 · +1558% YoY
- -₹97.09 CrNet loss · -60% margin
- -₹44.47 CrEBITDA · -27% margin
- ₹114 CrPaid-up capital
- 262Employees (provident fund records)
- +16%Revenue CAGR, 3 years
- +7%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Plasmagen Biosciences Private Limited are on its company page.
Detailed financial statements for PlasmaGen BioSciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of PlasmaGen BioSciences
4 dated milestones of PlasmaGen BioSciences across 15 years, from founding to its latest funding, stage changes and deals.
- Founded PlasmaGen BioSciences is founded.
- Funding First funding round of $25.0M.
- Milestone Reaches Minicorn status.
- Funding Latest funding round, Series D, of $16.7M.
Web traffic of PlasmaGen BioSciences
The website of PlasmaGen BioSciences (plasmagen.com) receives about 1.1K visits a month.
- Monthly visits1.1K
▲ 46.6% vs previous month
Websites whose visitors overlap most with PlasmaGen BioSciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
sangenebiotech.com | sangenebiotech.com | 100% | – | ||
| stringbio.com | 83% | 3.4K | #4,237,298 | View details | |
| anthembio.com | 82% | 9.8K | #1,599,242 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Plasmagen Biosciences
Complete news archive for PlasmaGen BioSciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PlasmaGen BioSciences
PlasmaGen BioSciences was founded in 2010 and raised its 1st funding round 7 years after it was founded.
PlasmaGen BioSciences is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
PlasmaGen BioSciences is a funded company, having raised a total of $84.55M across 5 funding rounds to date. The company's 1st funding round was a Series B of $25M, raised on Jul 2017.
PlasmaGen BioSciences has 262 employees.
The primary company behind PlasmaGen BioSciences, Plasmagen Biosciences Private Limited, reported revenue of ₹162 Cr for FY 2025, up 1558% year on year.
PlasmaGen BioSciences was established in 2010 in Bengaluru, India, within the biopharmaceutical sector. Focus is placed on products derived from blood plasma, such as albumin, immunoglobulins, coagulation factors, and specialty therapies. Operations aim to enhance accessibility of these treatments across India and emerging markets, supporting care in plasma protein and specialty therapy areas.
PlasmaGen BioSciences has 16 investors. Key investors include Eight Roads Ventures, RSM Pharma, Trigenesis Lifesciences, Kemwell, and F-Prime Capital.
The valuation of PlasmaGen BioSciences is $48.28M as of Mar 2023.
PlasmaGen BioSciences operates through Plasmagen Biosciences Private Limited.
The legal entities of PlasmaGen BioSciences currently have 6 directors, including Robert Mark Weisskoff, Prem Venkatachalam Pavoor, Gopal Sarda and others.